Inhibikase Therapeutics, Inc. (IKT) Income Statement
IKT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIKT revenue and net income
IKT profit margins
IKT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IKT quarterly EPS vs estimates
Inhibikase Therapeutics beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.11).
IKT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $260,500 | $123,440 | $3.1M | $698,468 | $1.1M | $4.0M | $2.1M | $967,386 |
| Cost of revenue | $60,499 | $26,272 | $13.6M | $6,723 | $11.4M | $893,802 | $2.6M | $3.6M | $1.8M | $846,386 |
| Gross profit | −$60,499 | −$26,272 | −$13.4M | $116,717 | $3.1M | $698,468 | −$1.4M | $4.0M | $305,245 | $121,000 |
| Research & development | $29.8M | $17.2M | $13.6M | $12.0M | $11.4M | $893,802 | $2.6M | $3.6M | $1.8M | $846,386 |
| Sales, general & admin | $23.6M | $11.4M | $6.7M | $6.2M | $6.5M | $2.6M | $4.3M | $2.5M | — | — |
| Total operating expenses | $52.0M | $28.6M | $6.7M | $18.2M | $14.8M | $2.8M | $5.7M | $2.1M | $2.5M | $734,287 |
| Operating income | −$52.0M | −$28.6M | −$20.1M | −$18.1M | −$14.8M | −$2.8M | −$5.7M | −$2.1M | −$405,130 | −$613,288 |
| Interest income | $3.7M | $1.1M | $891,205 | $74,453 | — | — | — | — | — | — |
| Interest expense | — | — | $74,453 | $74,453 | $19,923 | $29,402 | $24,835 | $30,332 | $0 | $0 |
| Income before taxes | −$48.3M | −$27.5M | −$19.0M | −$18.1M | −$14.8M | −$2.8M | −$5.7M | −$2.2M | −$436,075 | −$628,737 |
| Income taxes | — | — | −$148,906 | −$148,906 | $19,923 | $29,402 | $24,835 | −$161,141 | −$405,130 | −$15,449 |
| Net income | −$48.3M | −$27.5M | −$19.0M | −$18.1M | −$14.8M | −$2.9M | −$5.7M | −$2.2M | −$436,075 | −$628,737 |
| EBITDA | −$53.3M | −$27.5M | −$18.9M | −$18.0M | −$14.8M | −$2.8M | −$5.7M | −$2.1M | — | — |
| EPS (diluted) | −$0.48 | −$2.21 | −$3.57 | −$0.72 | −$0.86 | −$0.34 | −$0.55 | −$0.31 | −$0.02 | −$0.02 |
| Gross margin | — | — | −5,127.8% | 94.6% | 100.0% | 100.0% | −127.4% | 100.0% | 14.8% | 12.5% |
| Operating margin | — | — | −7,712.0% | −14,686.2% | −476.2% | −403.5% | −507.5% | −52.5% | −19.7% | −63.4% |
| Net margin | — | — | −7,304.8% | −14,625.9% | −477.5% | −411.9% | −511.9% | −53.3% | −21.2% | −65.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $26,274 | $0 | $0 | $0 | $1 | $79,569 |
| Cost of revenue | — | — | $36,811 | $23,688 | $24,157 | $12,654 | $6,567 | $6,568 | $6,569 | $6,568 | $6,568 | $6,568 |
| Gross profit | — | — | −$36,811 | −$23,688 | −$24,157 | −$12,654 | −$6,567 | −$6,568 | −$6,569 | −$6,568 | −$6,567 | $73,001 |
| Research & development | $13.4M | $10.8M | $6.4M | $7.6M | $5.3M | $10.5M | $7.2M | $4.2M | $3.1M | $2.8M | $3.0M | $3.2M |
| Sales, general & admin | $7.7M | $7.4M | $6.8M | $5.6M | $5.9M | $5.2M | $5.7M | $1.6M | $2.0M | $2.0M | $1.4M | $1.6M |
| Total operating expenses | $21.1M | $18.2M | $13.8M | $12.8M | $10.8M | $14.6M | $12.9M | $5.8M | $5.1M | $4.8M | $4.4M | $4.8M |
| Operating income | −$21.1M | −$18.2M | −$13.8M | −$12.8M | −$10.8M | −$14.6M | −$12.9M | −$5.8M | −$5.1M | −$4.8M | −$4.4M | −$4.8M |
| Interest income | $1.5M | — | $1.0M | $838,093 | $916,755 | $919,271 | $796,123 | $49,410 | $90,927 | $132,725 | $225,626 | $173,677 |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $661,606 | $55,917 |
| Income before taxes | −$19.6M | −$16.4M | −$12.7M | −$11.9M | −$9.9M | −$13.7M | −$12.1M | −$5.8M | −$5.0M | −$4.6M | −$4.2M | −$4.6M |
| Income taxes | — | — | — | — | — | — | — | — | $1 | $2 | $1 | $46,169 |
| Net income | −$19.6M | −$16.4M | −$12.7M | −$11.9M | −$9.9M | −$13.7M | −$12.1M | −$5.8M | −$5.0M | −$4.6M | −$4.2M | −$4.6M |
| EBITDA | −$19.6M | −$16.4M | −$13.1M | −$13.2M | −$11.2M | −$15.8M | −$12.1M | −$5.8M | −$5.0M | −$4.6M | −$4.2M | −$4.6M |
| EPS (diluted) | −$0.11 | −$0.10 | −$0.09 | −$0.13 | −$0.11 | −$0.15 | −$0.17 | −$0.65 | −$0.66 | −$0.73 | −$0.64 | −$0.86 |
| Gross margin | — | — | — | — | — | — | −25.0% | — | — | — | −656,700.0% | 91.7% |
| Operating margin | — | — | — | — | — | — | −49,207.2% | — | — | — | −440,356,600.0% | −5,993.4% |
| Net margin | — | — | — | — | — | — | −46,177.1% | — | — | — | −417,794,000.0% | −5,775.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IKT's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IKT financial results
Inhibikase Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $48.3 million. Diluted earnings per share came to −$0.48.
See the IKT stock overview for the latest quote and news, or the IKT chart for price history and technical indicators.
IKT income statement FAQ
Does Inhibikase Therapeutics have revenue?
Inhibikase Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Inhibikase Therapeutics profitable?
No. Inhibikase Therapeutics reported a net loss of $48.3 million in fiscal 2025.
How much does Inhibikase Therapeutics spend on research and development?
Inhibikase Therapeutics spent $29.8 million on research and development in fiscal 2025.
What are Inhibikase Therapeutics's earnings per share?
Inhibikase Therapeutics earned $-0.48 per diluted share in fiscal 2025, compared with $-2.21 a year earlier.
When will Inhibikase Therapeutics report its next earnings?
Inhibikase Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026 after the market closes.
When does Inhibikase Therapeutics's fiscal year end?
Inhibikase Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.